Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis. Calleja JL, et al. Among authors: gea f. Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15. Liver Int. 2015. PMID: 25113158 Clinical Trial.
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions.
Ruiz-Antorán B, Pascasio JM, Gea F, Barcena R, Larrubia J, Pérez ÁR, Sousa J, Romero GM, Solá R, de lR, Crespo J, Navarro J, Arenas J, Delgado M, Fernández RC, Planas R, Buti M, Forns X, Calleja JL. Ruiz-Antorán B, et al. Among authors: gea f. Value Health. 2014 Nov;17(7):A367. doi: 10.1016/j.jval.2014.08.822. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200769 Free article. No abstract available.
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Alonso S, et al. Among authors: gea f. J Viral Hepat. 2017 Apr;24(4):304-311. doi: 10.1111/jvh.12648. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935168 Free article.
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Calleja JL, et al. Among authors: gea f. J Hepatol. 2017 Jun;66(6):1138-1148. doi: 10.1016/j.jhep.2017.01.028. Epub 2017 Feb 9. J Hepatol. 2017. PMID: 28189751
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Crespo J, et al. Among authors: gea f. Clin Gastroenterol Hepatol. 2017 Jun;15(6):945-949.e1. doi: 10.1016/j.cgh.2017.02.020. Epub 2017 Feb 24. Clin Gastroenterol Hepatol. 2017. PMID: 28238958
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA. Puigvehí M, et al. Among authors: gea f. Liver Int. 2019 Jan;39(1):90-97. doi: 10.1111/liv.13950. Epub 2018 Nov 12. Liver Int. 2019. PMID: 30160363
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Hernández-Conde M, et al. Among authors: gea f. J Viral Hepat. 2019 Jan;26(1):55-64. doi: 10.1111/jvh.13008. Epub 2018 Oct 25. J Viral Hepat. 2019. PMID: 30265418
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Llaneras J, et al. Among authors: gea f. J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14. J Hepatol. 2019. PMID: 31203153 Free article. Clinical Trial.
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. Alonso López S, et al. Among authors: gea f. Hepatology. 2020 Dec;72(6):1924-1934. doi: 10.1002/hep.31588. Epub 2020 Nov 10. Hepatology. 2020. PMID: 33022803
57 results